US Pharma MarketingASCO26: RLTs bring the buzz, but commercial and tolerability qualms remain - Pharmaceutical Technology
RLTs were a hot topic at ASCO 2026, but certain limitations must be addressed to facilitate their widespread use in cancer care. RLTs were a hot topic at ASCO 2026, but experts note that certain limitations must be addressed to facilitate their widespread use in cancer care. The radiopharmaceutical drug class was catching attention at ASCO 2026. Credit: Love Employee / Shutterstock.com. Upon its rise to notoriety spearheaded by drugs like Novartis’ Pluvicto (lutetium Lu 177 vipivotide tetraxetan), the radiopharmaceutical field is capturing the attention of both industry and investors, as the cancer treatment paradigm increasingly shifts towards targeted combination…
RLTs were a hot topic at ASCO 2026, but certain limitations must be addressed to facilitate their widespread use in cancer care.
Source: Pharmaceutical Technology